PASG Key Statistics, Chart & Performance
The current stock price of PASG is 9.58 USD. In the past month the price decreased by -55.16%. In the past year, price decreased by -20.54%.
PASG Technical Analysis
PASG Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PASG. The financial health of PASG is average, but there are quite some concerns on its profitability.
PASG Financial Highlights
Over the last trailing twelve months PASG reported a non-GAAP Earnings per Share(EPS) of -14.4. The EPS increased by 38.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.04% | ||
| ROE | -145.45% | ||
| Debt/Equity | 0 |
PASG Forecast & Estimates
12 analysts have analysed PASG and the average price target is 40.39 USD. This implies a price increase of 321.63% is expected in the next year compared to the current price of 9.58.
PASG Ownership
PASG Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.46 | 394.585B | ||
| AMGN | AMGEN INC | 16.25 | 202.372B | ||
| GILD | GILEAD SCIENCES INC | 16.68 | 188.186B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.93 | 119.469B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.35 | 82.007B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.18 | 42.275B | ||
| INSM | INSMED INC | N/A | 31.892B | ||
| NTRA | NATERA INC | N/A | 29.062B | ||
| BIIB | BIOGEN INC | 12.52 | 28.432B | ||
| INCY | INCYTE CORP | 12.51 | 21.405B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PASG
Company Profile
Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2020-02-28. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
Company Info
PASSAGE BIO INC
One Commerce Square, 2005 Market Street, 39Th Floor
PHILADELPHIA PENNSYLVANIA 19103 US
CEO: Bruce Goldsmith
Employees: 60
Phone: 12678660312
PASSAGE BIO INC / PASG FAQ
What does PASG do?
Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2020-02-28. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
Can you provide the latest stock price for PASSAGE BIO INC?
The current stock price of PASG is 9.58 USD. The price increased by 7.64% in the last trading session.
Does PASG stock pay dividends?
PASG does not pay a dividend.
What is the ChartMill rating of PASSAGE BIO INC stock?
PASG has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is PASG stock listed?
PASG stock is listed on the Nasdaq exchange.
Can you provide the number of employees for PASSAGE BIO INC?
PASSAGE BIO INC (PASG) currently has 60 employees.
Can you provide the ownership details for PASG stock?
You can find the ownership structure of PASSAGE BIO INC (PASG) on the Ownership tab.